Hsa_circ_0016760 exacerbates the malignant development of non‑small cell lung cancer by sponging miR‑145‑5p/FGF5

Zhu,Zheng; Wu,Qiyong; Zhang,Ming; Tong,Jichun; Zhong,Bin; Yuan,Kai

doi:10.3892/or.2020.7899

Hsa_circ_0016760 exacerbates the malignant development of non‑small cell lung cancer by sponging miR‑145‑5p/FGF5

Authors:
- Zheng Zhu
- Qiyong Wu
- Ming Zhang
- Jichun Tong
- Bin Zhong
- Kai Yuan
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213000, P.R. China
Published online on: December 14, 2020 https://doi.org/10.3892/or.2020.7899
Pages: 501-512
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hsa_circ_0016760 expression has been reported to be increased in non‑small cell lung cancer (NSCLC). The present study was designed to explore the role and mechanism of hsa_circ_0016760 in regulating NSCLC progression. In total, 60NSCLC patients were followed‑up for 60 months after surgery. Hsa_circ_0016760 expression in tumor tissues and adjacent non‑tumor tissues of NSCLC patients was explored by reverse transcription quantitative polymerase chain reaction (RT‑qPCR). NSCLC cell proliferation was monitored by CCK‑8 assay and EdU experiment. Transwell assays were used for the detection of NSCLC cell migration and invasion. The target of hsa_circ_0016760 (or miR‑145‑5p) was validated by luciferase reporter gene assay and RNA immunoprecipitation experiment. A xenograft model was studied with nude mice. Immunohistochemical staining was applied for the detection of Ki67 expression in xenograft tumors. Hsa_circ_0016760/miR‑145‑5p/FGF5 expression in tissues and cells was investigated by RT‑qPCR and western blotting. Hsa_circ_0016760 was aberrantly upregulated in NSCLC, which was associated with poor prognosis of patients (P<0.05). Hsa_circ_0016760 silencing suppressed NSCLC cell proliferation, migration and invasion in vitro (P<0.01). Hsa_circ_0016760 facilitated FGF5 expression via sponging miR‑145‑5p. The miR‑145‑5p upregulation or FGF5 downregulation reversed the promoting effect of hsa_circ_0016760 on NSCLC cell proliferation, migration and invasion in vitro (P<0.01). In addition, hsa_circ_0016760 silencing inhibited tumor growth in vivo (P<0.01), and decreased Ki67 expression in xenograft tumors. In conclusion, hsa_circ_0016760 exacerbated the malignant development of NSCLC by sponging miR‑145‑5p/FGF5.

View Figures

View References

1	Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, et al: The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 6:752018. View Article : Google Scholar : PubMed/NCBI
2	He W, Zhang H, Wang Y, Zhou Y, Luo Y, Cui Y, Jiang N, Jiang W, Wang H, Xu D, et al: CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9. BMC Cancer. 18:4002018. View Article : Google Scholar : PubMed/NCBI
3	Chen S, Shi F, Zhang W, Zhou Y and Huang J: miR-744-5p inhibits non-small cell lung cancer proliferation and invasion by directly targeting PAX2. Technol Cancer Res Treat. 18:15330338198769132019. View Article : Google Scholar : PubMed/NCBI
4	Nicolaou A, Northoff BH, Zhao Z, Kohlmaier A, Sass K, Rose-John S, Steffens S, Weber C, Teupser D and Holdt LM: The ADAM17 metalloproteinase maintains arterial elasticity. Thromb Haemost. 118:210–213. 2018. View Article : Google Scholar : PubMed/NCBI
5	Zhang J, Hou L, Liang R, Chen X, Zhang R, Chen W and Zhu J: CircDLST promotes the tumorigenesis and metastasis of gastric cancer by sponging miR-502-5p and activating the NRAS/MEK1/ERK1/2 signaling. Mol Cancer. 18:802019. View Article : Google Scholar : PubMed/NCBI
6	Zhang S, Zeng X, Ding T, Guo L, Li Y, Ou S and Yuan H: Microarray profile of circular RNAs identifies hsa_circ_0014130 as a new circular RNA biomarker in non-small cell lung cancer. Sci Rep. 8:28782018. View Article : Google Scholar : PubMed/NCBI
7	Li Y, Hu J, Li L, Cai S, Zhang H, Zhu X, Guan G and Dong X: Upregulated circular RNA circ_0016760 indicates unfavorable prognosis in NSCLC and promotes cell progression through miR-1287/GAGE1 axis. Biochem Biophys Res Commun. 503:2089–2094. 2018. View Article : Google Scholar : PubMed/NCBI
8	Chang Y, Yan W, Sun C, Liu Q, Wang J and Wang M: miR-145-5p inhibits epithelial-mesenchymal transition via the JNK signaling pathway by targeting MAP3K1 in non-small cell lung cancer cells. Oncol Lett. 14:6923–6928. 2017.PubMed/NCBI
9	Zhao T, Qian K and Zhang Y: High expression of FGF5 is an independent prognostic factor for poor overall survival and relapse-free survival in lung adenocarcinoma. J Comput Biol. 27:948–957. 2020. View Article : Google Scholar : PubMed/NCBI
10	Xiao MS and Wilusz JE: An improved method for circular RNA purification using RNase R that efficiently removes linear RNAs containing G-quadruplexes or structured 3′ ends. Nucleic Acids Res. 47:8755–8769. 2019. View Article : Google Scholar : PubMed/NCBI
11	Chen Y, Peng C, Chen J, Chen D, Yang B, He B, Hu W, Zhang Y, Liu H, Dai L, et al: WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 18:1272019. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Zhang X, Yan Y, Lei X, Li A, Zhang H, Dai Z, Li X, Chen W, Lin W, Chen F, et al: Circular RNA alterations are involved in resistance to avian leukosis virus subgroup-J-induced tumor formation in chickens. Oncotarget. 8:34961–34970. 2017. View Article : Google Scholar : PubMed/NCBI
14	Shi P, Sun J, He B, Song H, Li Z, Kong W, Wang J, Wang J and Xue H: Profiles of differentially expressed circRNAs in esophageal and breast cancer. Cancer Manag Res. 10:2207–2221. 2018. View Article : Google Scholar : PubMed/NCBI
15	Wang Y, Li Y, He H and Wang F: Circular RNA circ-PRMT5 facilitates non-small cell lung cancer proliferation through upregulating EZH2 via sponging miR-377/382/498. Gene. 720:1440992019. View Article : Google Scholar : PubMed/NCBI
16	Zhang H, Wang X, Hu B, Zhang F, Wei H and Li L: Circular RNA ZFR accelerates non-small cell lung cancer progression by acting as a miR-101-3p sponge to enhance CUL4B expression. Artif Cells Nanomed Biotechnol. 47:3410–3416. 2019. View Article : Google Scholar : PubMed/NCBI
17	Chen T, Yang Z, Liu C, Wang L, Yang J, Chen L and Li W: Circ_0078767 suppresses non-small-cell lung cancer by protecting RASSF1A expression via sponging miR-330-3p. Cell Prolif. 52:e125482019. View Article : Google Scholar : PubMed/NCBI
18	Gan TQ, Xie ZC, Tang RX, Zhang TT, Li DY, Li ZY and Chen G: Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data. Tumour Biol. 39:10104283176916832017. View Article : Google Scholar : PubMed/NCBI
19	Lu Q, Shan S, Li Y, Zhu D, Jin W and Ren T: Long noncoding RNA SNHG1 promotes non-small cell lung cancer progression by up-regulating MTDH via sponging miR-145-5p. FASEB J. 32:3957–3967. 2018. View Article : Google Scholar : PubMed/NCBI
20	Jin M, Ren J, Luo M, You Z, Fang Y, Han Y, Li G and Liu H: Long non-coding RNA JPX correlates with poor prognosis and tumor progression in non-small-cell lung cancer by interacting with miR-145-5p and CCND2. Carcinogenesis. 41:634–645. 2020. View Article : Google Scholar : PubMed/NCBI
21	Wei CM, Zhao XF, Qiu HB, Ming Z, Liu K and Yan J: The long non-coding RNA PVT1/miR-145-5p/ITGB8 axis regulates cell proliferation, apoptosis, migration and invasion in non-small cell lung cancer cells. Neoplasma. 67:802–812. 2020. View Article : Google Scholar : PubMed/NCBI
22	Zhou Y, Yu Q, Chu Y, Zhu X, Deng J, Liu Q and Wang Q: Downregulation of fibroblast growth factor 5 inhibits cell growth and invasion of human nonsmall-cell lung cancer cells. J Cell Biochem. Dec 5–2018.(Epub ahead of print).doi: https://doi.org/10.1002/jcb.28107.
23	Han D, Wang M, Yu Z, Yin L, Liu C, Wang J, Liu Y, Jiang S, Ren Z and Yin J: FGF5 promotes osteosarcoma cells proliferation via activating MAPK signaling pathway. Cancer Manag Res. 11:6457–6466. 2019. View Article : Google Scholar : PubMed/NCBI
24	Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vörösmarty B, Brankovic J, Lackner A, Leopoldi A, et al: FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo. Oncotarget. 8:87750–87762. 2017. View Article : Google Scholar : PubMed/NCBI
25	Huang Y, Wang H and Yang Y: Expression of fibroblast growth factor 5 (FGF5) and its influence on survival of breast cancer patients. Med Sci Monit. 24:3524–3530. 2018. View Article : Google Scholar : PubMed/NCBI